TotalRisk+
The First Polygenic-Monogenic Cancer Risk Assessment
Transform Care with the Most Comprehensive AI-Powered Cancer Risk Tool
Why Combine Polygenic & Monogenic Testing?
5-10% of cancers are caused by high-risk single-gene mutations*, which polygenic risk scores alone cannot detect. Studies show combining polygenic and monogenic testing improves risk detection, reducing false positives and enabling earlier interventions for high-risk individuals**.
With TotalRisk+’s AI-powered dual approach, clinicians gain a broader, more precise risk evaluation, identifying both rare and common genetic risks – helping lead to better prevention and patient outcomes.
What is TotalRisk+
TotalRisk+ is the only AI-powered tool combining polygenic risk scoring (PRS) and monogenic testing for a complete cancer genetic risk assessment.
What It Covers:
- Predicts genetic predisposition to breast, colon, and prostate cancer
- Integrates 29-gene monogenic panel (e.g., BRCA, Lynch Syndrome)
- Includes optional genetic counseling for pre- and post-test support
TotalRisk+ Gene List
APC, BRCA1, BRCA2, BMPR1A, CDH1, EPCAM, GREM1, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53, HOXB13, CHEK2, ATM, GREM1, AXIN2, NTHL1, MSH3, RAD51C, RAD51D, BARD1
Key Advantages of TotalRisk+
AI-powered insights
integrating monogenic and polygenic risk scores (PRS)
More accurate risk prediction
than single or polygenic methods alone
Seamless integration
into EMRs for real-time decision support
Actionable recommendations
for personalized prevention and treatment
Our Collaborators
Try the only AI-powered, polygenic-monogenic cancer risk tool
References:
*Ngeow J, Eng C. Precision medicine in heritable cancer: when somatic tumour testing and germline mutations meet. NPJ Genom Med. 2016;1:15006. https://www.nature.com/articles/npjgenmed20156
** Bolze, A., Kiser, D., Schiabor Barrett, K. M., Hajek, C., Cirulli, E. T., & Grzymski, J. J. (2024). Combining rare and common genetic variants improves population risk stratification for breast cancer. Genetics in Medicine Open, Volume 21, Article 101826. https://doi.org/10.1016/j.gimo.2024.101826